How to Evaluate Pharma PMPs Before Committing Budget
A deal evidence card and pre and post-launch validation checklist for private marketplace deals in pharma programmatic.
The short answer
Private marketplace deals promise access to specific inventory, often at a premium price, with more control than the open exchange. In pharma, PMPs are common for endemic health publishers and curated HCP or DTC packages. But a deal ID is only a label. What matters is what actually delivers through it. Many PMPs deliver differently from how they were described.
Build a deal evidence card
Before committing budget, ask the seller to fill in a short card.
| Field | What to ask |
|---|---|
| Inventory | Which domains or apps are included? Is the list fixed or does it change? |
| Formats | Which sizes and video lengths? |
| Audience | Is audience data applied? From what source? |
| Floor price | What is the floor, and does it change? |
| Volume | Expected available impressions per week at your targeting |
| Exclusivity | Is this inventory also available elsewhere, including open exchange? |
| Supply path | Which exchange, and is the seller listed in sellers.json? |
| Quality | Verification results from recent campaigns |
Validate before launch
- Check the domain list against ads.txt authorization. See ads.txt, sellers.json, and schain.
- Compare against open-market access. If the same inventory is available on the open exchange for less, the deal needs another justification.
- Confirm the deal is set up correctly in your DSP, with the right targeting applied on top.
Validate after launch
Within the first two weeks:
- Compare delivered domains and apps to the promised list.
- Check viewability, invalid traffic, and context against expectations.
- Check volume against the seller's estimate.
- Compare the effective price, including fees, with alternatives.
Deals that deliver mostly outside their promised inventory, or at much lower volume, should be renegotiated or paused.
When PMPs are worth it
PMPs make sense when they provide:
- Access to inventory not available otherwise.
- Better quality, verified by your own data.
- Audience data applied by the publisher that you cannot replicate.
- Operational simplicity that outweighs the premium.
They are harder to justify when they repackage open-market inventory at a higher price.
Compare transaction types
PMPs are one of several ways to buy. See direct, PMP, or open auction for how to choose among them.
Practical takeaway
Require a completed deal evidence card before activating any new PMP. Review delivered inventory against it in week two, and keep or cut the deal based on what delivered.
Sources
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.